Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Payables (2016 - 2025)

IGC Pharma (IGC) has disclosed Payables for 15 consecutive years, with $628000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 18.23% to $628000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $628000.0, a 18.23% decrease, with the full-year FY2025 number at $883000.0, up 14.23% from a year prior.
  • Payables was $628000.0 for Q3 2025 at IGC Pharma, down from $933000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.6 million in Q3 2023 to a low of $360000.0 in Q4 2021.
  • A 5-year average of $735421.1 and a median of $672000.0 in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: tumbled 68.06% in 2021, then skyrocketed 241.45% in 2023.
  • IGC Pharma's Payables stood at $360000.0 in 2021, then increased by 29.44% to $466000.0 in 2022, then skyrocketed by 39.06% to $648000.0 in 2023, then grew by 28.86% to $835000.0 in 2024, then fell by 24.79% to $628000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Payables are $628000.0 (Q3 2025), $933000.0 (Q2 2025), and $883000.0 (Q1 2025).